EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the treatment volume and removal rate of Rheocarna : A novel adsorption‐type blood purification device for patients with chronic limb‐threatening ischemia

Atsushi Ohkubo, Takatoshi Sakurasawa, Yuki Hoshikawa, Mana Usui, Misaki Hoshi, Takuto Shiga, Masaya Deushi, Shigeto Komori, Ayako Itagaki, Hiroko Yamamoto, Hiroshi Seshima, Naoki Kurashima und 2 weitere

Therapeutic Apheresis and Dialysis · 2023-12 · 27 (6) · 1017-1022

DOI: 10.1111/1744-9987.14050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 17.08.2023. Verfasst von Atsushi Ohkubo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Hypercholesterolemia, Blood Component Removal, Peripheral Arterial Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic limb‐threatening ischemia (CLTI) is a clinical syndrome defined by peripheral arterial disease (PAD) combined with rest pain, gangrene, or leg ulceration for longer than two weeks resulting in lower extremity amputation. In recent years, low‐density lipoprotein apheresis (LDL‐A) has been implemented for PAD treatment. However, it has not been possible to ensure insurance coverage for patients with lower LDL levels than 140 mg/dL under cholesterol‐lowering drugs. Rheocarna is a novel adsorption‐type blood purification device for the treatment of CLTI by adsorbing LDL and fibrinogen (Fib) that is not constrained by hypercholesterolemia and is not amenable to or nonresponsive to revascularization surgery. The only requirements for use are that the blood flow rate increases up to 200 mL/min gradually.

Methods

To evaluate the applicability of this treatment procedure, we compared the removal rates of Fib and LDL following Rheocarna therapy using various blood treatment volumes (6, 10.5, and 19.5 L).

Results

Fib and LDL removal rates were about 20% and 15%–25% per treatment, with no significant differences between treatment volumes. Following treatment with Rheocarna, blood pressure tends to decrease at first, which later increases, and the higher the treatment volume, the longer the time of low blood pressure tended to be.

Conclusion

Although no significant difference was found in the removal rate of Fib and LDL in response to increase volume to 6 L or beyond in this study, the 6 L volume is considered effective enough for the removal of Fib and LDL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaBlood Component RemovalPeripheral Arterial DiseaseHumansChronic Limb-Threatening IschemiaAdsorptionTreatment OutcomeIschemia

Stichwörter der Autor:innen

fibrinogenhemoadsorptionlow-density lipoprotein cholesterolremoval rate

Autor:innen und Institutionen

  • Medical Engineering Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
  • Department of Nephrology, Tokyo Medical and Dental University, Tokyo, Japan.

Zitieren

APA

Ohkubo, A., Sakurasawa, T., Hoshikawa, Y., Usui, M., Hoshi, M., Shiga, T., Deushi, M., Komori, S., Itagaki, A., Yamamoto, H., Seshima, H., Kurashima, N., Iimori, S., & Naito, S. (2023). Evaluation of the treatment volume and removal rate of Rheocarna : A novel adsorption‐type blood purification device for patients with chronic limb‐threatening ischemia. Therapeutic Apheresis and Dialysis, 27(6), 1017-1022. https://doi.org/10.1111/1744-9987.14050

Vancouver

Ohkubo A, Sakurasawa T, Hoshikawa Y, Usui M, Hoshi M, Shiga T, et al. Evaluation of the treatment volume and removal rate of Rheocarna : A novel adsorption‐type blood purification device for patients with chronic limb‐threatening ischemia. Therapeutic Apheresis and Dialysis. 2023;27(6):1017-1022. doi:10.1111/1744-9987.14050

BibTeX
@article{Ohkubo2023,
  author = {Ohkubo, Atsushi and Sakurasawa, Takatoshi and Hoshikawa, Yuki and Usui, Mana and Hoshi, Misaki and Shiga, Takuto and Deushi, Masaya and Komori, Shigeto and Itagaki, Ayako and Yamamoto, Hiroko and Seshima, Hiroshi and Kurashima, Naoki and Iimori, Soichiro and Naito, Shotaro},
  title = {Evaluation of the treatment volume and removal rate of Rheocarna : A novel adsorption‐type blood purification device for patients with chronic limb‐threatening ischemia},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2023},
  volume = {27},
  number = {6},
  pages = {1017--1022},
  doi = {10.1111/1744-9987.14050}
}
Kostenlos starten →